The video presents the 2nd hackathon event held at PRBB and gives an insight into the eTOX project.
The eTOX project aims to develop a drug safety database from the pharmaceutical industry legacy toxicology reports and public toxicology data, innovative in silico strategies and novel software tools to better predict the toxicological profiles of small molecules in early stages of the drug development pipeline. The eTOX project is funded by the IMI and coordinated by the GRIB (IMIM-UPF).
The Jury of the Award for Biomedical Research of the Banco Sabadell Foundation decided to give this prize to Núria López-Bigas, leader of the Biomedical Genomics group of GRIB (UPF-IMIM), for her contribution to the development of new bioinformatics methods to study cancer genomes. Her work opens up new avenues for the classification of cancer patients according to their tumors carry mutations and thus advance the implementation of the most appropriate individualized for each patient therapies.
"This award helps to give visibility to the Biomedical Research and lets the society know the people who do research. It is a social recognition of the work we do and it is an honor for me that the research done in my group has been recognized" said Núria when knowing the news."In Barcelona, high quality biomedicine research is made with leading research groups in this field to develop high-impact projects for society. For me, it is a luxury to do research in this environment and appear next to the remains of scientists who have been honored with this award".
The project NONCODRIVERS "Finding noncoding cancer drivers", aims to characterize the role of mutations in non-coding regions in the most prevalent tumours of the population. The work will count with the collaboration of the International Cancer Genome Consortium, an organization created for the classification of the molecular profile of 50 different types of cancer. The project aims to identify those non-coding alterations that are more relevant for tumour biology through computational methods and will explore new therapeutic strategies that can revert its effects by means of the creation of the corresponding cellular models. The project is funded for the period 2016-2021 by the European Research Council (ERC) with an ERC Consolidator grants given to Nuria López-Bigas, head of the Biomedical Genomics group of GRIB.